Laurion Capital Management LP decreased its holdings in Magenta Therapeutics Inc (NASDAQ:MGTA) by 18.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 284,124 shares of the company’s stock after selling 65,876 shares during the quarter. Laurion Capital Management LP’s holdings in Magenta Therapeutics were worth $3,412,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Casdin Capital LLC purchased a new stake in Magenta Therapeutics in the 2nd quarter valued at $27,484,000. FIL Ltd raised its position in Magenta Therapeutics by 15.8% in the 3rd quarter. FIL Ltd now owns 956,784 shares of the company’s stock valued at $11,491,000 after purchasing an additional 130,312 shares during the last quarter. Opaleye Management Inc. purchased a new stake in Magenta Therapeutics in the 2nd quarter valued at $7,425,000. Harvard Management Co. Inc. purchased a new stake in Magenta Therapeutics in the 2nd quarter valued at $4,490,000. Finally, Voya Investment Management LLC purchased a new stake in Magenta Therapeutics in the 2nd quarter valued at $3,387,000. Hedge funds and other institutional investors own 30.79% of the company’s stock.

Shares of MGTA opened at $7.83 on Friday. Magenta Therapeutics Inc has a 1 year low of $6.10 and a 1 year high of $16.33.

Magenta Therapeutics (NASDAQ:MGTA) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.18. Sell-side analysts expect that Magenta Therapeutics Inc will post -3.19 EPS for the current year.

Separately, Zacks Investment Research upgraded shares of Magenta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $19.33.

ILLEGAL ACTIVITY WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at

About Magenta Therapeutics

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Read More: What is the Coverage Ratio?

Want to see what other hedge funds are holding MGTA? Visit to get the latest 13F filings and insider trades for Magenta Therapeutics Inc (NASDAQ:MGTA).

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with's FREE daily email newsletter.